Trials / Completed
CompletedNCT06004960
A Study to Assess the Mass Balance Recovery (Absorption, Distribution, Metabolism and Excretion) of [14C]CCX168 in Healthy Participants
An Open-Label, Phase 1 Study in Healthy Volunteers to Evaluate the Mass Balance Recovery and Metabolic Disposition of a Single Oral Dose of [14C]CCX168
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Amgen · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of this study is to perform mass balance following a single oral dose of \[14C\]CCX168 in healthy adult male participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [14C]CCX168 | Administered orally. |
Timeline
- Start date
- 2014-10-20
- Primary completion
- 2014-12-05
- Completion
- 2014-12-05
- First posted
- 2023-08-22
- Last updated
- 2023-08-22
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06004960. Inclusion in this directory is not an endorsement.